| Project/Area Number |
16K21118
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
Respiratory organ internal medicine
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Nagai Hiroki 京都大学, 医学研究科, 特定助教 (80711605)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 胸腺腫瘍 / DOTATOC / Octreotide / オクトレオチド / Octreotide LAR/PSL / 効果予測因子 / 核医学(PET） / 稀少癌 |
|---|
| Outline of Final Research Achievements |
In this research, we investigated whether 68Ga-DOTATOC PET/CT could be a biomarker for efficacy of combination chemotherapy of octreotide LAR and prednisone against advanced thymic tumor and thymic cancer.
Ten patients with advanced thymic tumor or thymic cancer ware enrolled. We evaluated somatostatin receptor expression by 68Ga-DOTATOC PET/CT before chemotherapy administration and later performed combination chemotherapy of octreotide LAR and prednisone. The response rate was 10 % and the disease control rate was 40 %. And, severe adverse events were not found during this treatment.We could confirm the uptake of 68Ga-DOTATOC in the metastatic lesions as well as the primary lesions. However, there was no correlation between the uptake of 68Ga-DOTATOC and the efficacy of combination chemotherapy of octreotide LAR and prednisone.
|
